(Q43430943)

23 November 2017

title

Does neoadjuvant bevacizumab increase surgical complications in breast surgery? (English)

1 reference

23 November 2017

1 reference

8

E P Winer

1 reference

23 November 2017

M Golshan

1

1 reference

23 November 2017

J E Garber

2

1 reference

23 November 2017

R Gelman

3

1 reference

23 November 2017

Nadine Tung

4

1 reference

23 November 2017

B L Smith

5

1 reference

23 November 2017

S Troyan

6

1 reference

23 November 2017

C C Greenberg

7

1 reference

23 November 2017

P Ryan

9

1 reference

23 November 2017

publication date

30 September 2010

1 reference

Annals of Surgical Oncology

23 November 2017

published in

1 reference

23 November 2017

volume

18

1 reference

23 November 2017

issue

3

1 reference

23 November 2017

page(s)

733-737

1 reference

https://scigraph.springernature.com/pub.10.1245/s10434-010-1366-8

23 November 2017

exact match

0 references

cites work

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1366-8

Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1366-8

Complications associated with postoperative antibiotic prophylaxis after breast surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1366-8

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1366-8

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1366-8

A review on bevacizumab and surgical wound healing: an important warning to all surgeons

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1366-8

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1366-8

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1366-8

The impact of immediate breast reconstruction on the technical delivery of postmastectomy radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1366-8

New trends in breast cancer management: is the era of immediate breast reconstruction changing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1366-8

Morbidity and mortality following breast cancer surgery in women: national benchmarks for standards of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1366-8

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1366-8

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1366-8

Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-1366-8

10.1245/S10434-010-1366-8

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

23 November 2017

1043413784

0 references

1 reference